Johnson & Johnson $JNJ Holdings Raised by Czech National Bank

Czech National Bank increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 611,668 shares of the company’s stock after purchasing an additional 23,539 shares during the quarter. Johnson & Johnson accounts for about 0.8% of Czech National Bank’s investment portfolio, making the stock its 19th largest holding. Czech National Bank’s holdings in Johnson & Johnson were worth $113,415,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $35,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. Finally, Vermillion & White Wealth Management Group LLC raised its position in shares of Johnson & Johnson by 66.4% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after purchasing an additional 150 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. Argus set a $210.00 price objective on Johnson & Johnson in a research report on Wednesday, October 15th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Friday, October 31st. Bank of America boosted their target price on shares of Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday. Finally, Barclays raised their price target on shares of Johnson & Johnson from $176.00 to $197.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $210.25.

Johnson & Johnson Stock Down 1.0%

Johnson & Johnson stock opened at $208.23 on Friday. The company’s 50-day moving average price is $197.78 and its two-hundred day moving average price is $178.67. The stock has a market cap of $501.68 billion, a price-to-earnings ratio of 20.10, a PEG ratio of 2.28 and a beta of 0.36. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $215.18. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion for the quarter. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s payout ratio is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.